1. Home
  2. COOK vs NKTX Comparison

COOK vs NKTX Comparison

Compare COOK & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Traeger Inc.

COOK

Traeger Inc.

HOLD

Current Price

$0.85

Market Cap

145.2M

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.68

Market Cap

132.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COOK
NKTX
Founded
1985
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.2M
132.8M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
COOK
NKTX
Price
$0.85
$2.68
Analyst Decision
Hold
Strong Buy
Analyst Count
7
5
Target Price
$2.04
$13.25
AVG Volume (30 Days)
251.6K
701.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
60.29
33.33
EPS
N/A
N/A
Revenue
$604,072,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$1.31
52 Week High
$2.42
$2.74

Technical Indicators

Market Signals
Indicator
COOK
NKTX
Relative Strength Index (RSI) 42.66 72.33
Support Level $0.85 $1.95
Resistance Level $1.05 $2.74
Average True Range (ATR) 0.07 0.15
MACD -0.00 0.06
Stochastic Oscillator 50.35 98.00

Price Performance

Historical Comparison
COOK
NKTX

About COOK Traeger Inc.

Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: